Drug intelligence / Profile preview

CH-25

Development stage
Unknown
Lead developer
Curanter
Administration
Oral
01

Overview

CH-25 is a homeopathic remedy developed and marketed by Curanter Homeo, a retail company based in Patna, India. The product is available in oral formulations, including drops and tablets. As a homeopathic preparation, it is sold as a finished retail product rather than a drug candidate undergoing clinical development. There is no specific information available regarding its active ingredients, biological targets, or therapeutic indications, and it lacks documented pharmacological mechanisms or clinical trial evidence.

Brand names
CH-25CH25CH 25
Other names
CH-25 dropsCH25 dropsCH 25 dropsCH-25 tabletsCH25 tabletsCH 25 tablets

Beyond the preview

Go deeper on CH-25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH-25.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call